Tenpoint Therapeutics Launches Yuvezzi Presbyopia Eye Drop in the US

Key Takeaways

• Tenpoint Therapeutics has launched Yuvezzi, a once-daily prescription eye drop for adults with presbyopia, in the United States
• Yuvezzi is the first dual-agent treatment combining carbachol and brimonidine to improve near vision with sustained efficacy and tolerability
• The therapy is accessible through both an e-pharmacy partner and retail pharmacies

Tenpoint Therapeutics announced the US availability of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults.

Yuvezzi is the first and only approved dual-agent eye drop that combines carbachol and brimonidine tartrate. The two active ingredients work together to deliver sustained improvement in near vision while maintaining a strong profile for tolerability and safety, according to the company. The prescription treatment is available nationwide and can be dispensed through Tenpoint’s e-pharmacy partner, PHILRx, as well as through local retail pharmacies, offering patients multiple access options.

“With the availability of Yuvezzi, we are proud to offer adults with presbyopia a differentiated, one-drop, once-daily eye drop that improves near vision,” said Henric Bjarke, CEO of Tenpoint Therapeutics. “Yuvezzi is now broadly available through both our e-pharmacy partner and at retail pharmacies, maximizing flexibility for patients. Developed in close partnership with eye care professionals, Yuvezzi was intentionally designed to address real-world needs of people experiencing the effects of aging eyes, and we are excited to now bring this therapy to patients across the US”

Previously known as Brimochol PF, Yuvezzi was approved by the FDA in January 2026. The FDA approval was supported by positive results from two phase 3 clinical trials, BRIO I and BRIO II. In BRIO I, the combination therapy demonstrated a superior benefit compared with each individual active ingredient alone, meeting the FDA’s requirement for approval of a fixed-dose combination therapy. In the second study, BRIO II, which was vehicle-controlled, Yuvezzi achieved all primary efficacy endpoints, delivering statistically significant improvements of 3 lines or more in binocular uncorrected near visual acuity (BUNVA) over an 8-hour period, without a loss of 1 line or more in binocular uncorrected distance visual acuity (BUDVA).

“As we age, blurry close-up vision can turn simple, everyday moments like reading a text, checking a receipt, or reviewing a menu into a frustrating challenge,” said Carol Kearney, Chief Commercial Officer of Tenpoint Therapeutics. “Yuvezzi is designed to help adults see up close more clearly with the ease of a single drop, once-daily dosing, providing a new option for those who want to spend less time searching for reading glasses during work, at home, and on the go.”

Ms. Kearney added that Tenpoint plans to support eye care providers with education, resources, and product samples to facilitate adoption in clinical practice.

For more information, including full prescribing details, visit www.YUVEZZI.com.

Originally published online on Eyewire+.